All In Biotech

Drug Trial Radar · NCT07761429

A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

402

Planned (sponsor's estimate)

Start

Jul 8, 2026

Primary completion

Dec 30, 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned enrollment of 402 patients.Primary Endpoint is Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) based on RECIST 1.1 Secondary Endpoints included ORR、PFS、DOR;Incidence and severity of Adverse Events (AE), Serious Adverse Events (SAE), and abnormal laboratory parameters.

Conditions

  • Cancer of Unknown Primary Site

Interventions

  • F520 combined with chemotherapyDrug

    F520: 200 mg per dose, intravenous infusion, infusion time \>30 minutes, Q3W; maximum 2 years. Refer to drug preparation manual for details. Paclitaxel: 175 mg/m², intravenous infusion, infusion time \>3 hours, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details. Carboplatin: AUC 5, intravenous infusion, infusion time \>30 minutes, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details.

  • placebo combined with chemotherapyDrug

    Placebo: 200 mg per dose, intravenous infusion, infusion time \>30 minutes, Q3W; maximum 2 years. Refer to drug preparation manual for details. Paclitaxel: 175 mg/m², intravenous infusion, infusion time \>3 hours, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details. Carboplatin: AUC 5, intravenous infusion, infusion time \>30 minutes, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by IRCTime frame: 2years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai tumor hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.